Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03210350
Other study ID # CH29011702
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2017
Est. completion date September 30, 2018

Study information

Verified date November 2018
Source Corniche Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It had been shown that high percentage of severe preeclampsia patients got a high cerebral perfusion pressure (CPP) due to abnormal autoregulation of cerebral blood vessels with associated endothelial dysfunction and disrupted blood brain barrier. Moreover, patients with high CPP is more likely to present with headache compared to other patients with normal CPP.In this particular scenario, use of magnesium sulphate is associated with marked reduction of CPP and. hence prevention of cerebral damage.This hypothesis was confirmed by new magnetic resonance techniques that demonstrated brain edema in eclampsia/ severe preeclampsia patient mostly due to vasogenic edema and less commonly attributed to cytotoxic edema.

Changes in the optic nerve sheath diameter (ONSD) mirrors the changes in the Intracranial pressure(ICP), subsequently when the intracranial pressure increases the optic nerve sheath diameter (ONDS) also increases.

The aim of this study is to determine the effect Magnesium sulphate infusion on intracranial pressure, in patients presented with severe preeclampsia by measuring changes in the ONSD using ultrasound examination.


Description:

30 obstetric patients admitted to the HDU in Corniche Hospital for treatment of severe preeclampsia. Patients with the following criteria will be excluded from the current work: Patients undergone cranial or eye surgeries, Patients with known intracranial pathology, Patients suffering from glaucoma or any other eye pathology that prevent clear identification of the optic nerve, and Patients on drugs that may affect the cerebrospinal fluid [based on operator decision].

In this prospective pilot study, patients who will fulfill the inclusion criteria will be recruited at the time of admission in HDU by the investigators. The ONDS will be measured before the commencement of Magnesium sulphate infusion, 1hr after finishing the loading dose, 6 and 24 hrs after infusion started. Patients will be in supine position with the head of the bed less than 20 degrees. High frequency (7.5 MHz) linear probe will be used; it will be placed gently over both closed eye after liberal application of sterile gel, the patient will be instructed to look forward to align the optic nerve directly opposite to the probe. The ONSD will be measured 3mm behind the optic disc in both the sagittal and transverse planes and an average will be calculated and recorded. In the absence of complete visualization of the optic disc, the largest viewed diameter will be taken as the maximal ONSD. Hemodynamic variables & oxygen saturation will be recorded at the same times.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 30, 2018
Est. primary completion date July 30, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- obstetric patients admitted to the HDU at Corniche Hospital for treatment of severe preeclampsia

Exclusion Criteria:

- (1) Patients undergone cranial or eye surgeries, (2) Patients with known intracranial pathology, (3) Patients suffering from glaucoma or any other eye pathology that prevent clear identification of the optic nerve, (4) Patients on drugs that may affect the cerebrospinal fluid

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Optic nerve sheath diameter
Optic nerve sheath diameter measurement using ultrasound

Locations

Country Name City State
United Arab Emirates Corniche Hospital Abu Dhabi

Sponsors (1)

Lead Sponsor Collaborator
Corniche Hospital

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Optic nerve sheath diameter from baseline after magnesium Sulfate administration Change in Optic nerve sheath diameter from baseline at 1, 6 and 24 hours after completion of Magnesium sulfate loading dose 1,6 and 24 hours
See also
  Status Clinical Trial Phase
Terminated NCT04243278 - Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC) Early Phase 1
Not yet recruiting NCT03318211 - Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Phase 4
Completed NCT05594056 - Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia. N/A
Recruiting NCT03761888 - Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Not yet recruiting NCT06373367 - Preeclampsia Educational Program Study (PrEPS) N/A
Not yet recruiting NCT04855513 - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial N/A
Not yet recruiting NCT05232994 - Metformin and Esomeprazole For Preterm Pre-eclampsia Phase 1
Completed NCT04392375 - Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Phase 4
Recruiting NCT03978767 - Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Phase 2
Completed NCT04236258 - Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Phase 4
Completed NCT04756661 - Uterotonics for Severe Preeclampsia N/A
Active, not recruiting NCT04660032 - Nudge to Drive Transitions of Care N/A
Completed NCT04103489 - The Use of Eculizumab in HELLP Syndrome Phase 1
Enrolling by invitation NCT04794855 - Risk Prediction Model of Preeclampsia
Recruiting NCT04311749 - Expanded NIPT for Pregnancy Complications
Active, not recruiting NCT06359015 - Metformin and Esomeprazole in Preterm Pre-eclampsia Phase 4
Recruiting NCT05610774 - Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine N/A
Completed NCT03815110 - Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
Completed NCT03451266 - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia Phase 1
Active, not recruiting NCT06360601 - Intravenous Labetalol Versus Hydralazine in Preeclampsia Phase 1/Phase 2